Molecular Biomarkers and Signaling Pathways of Cancer Stem Cells in Colorectal Cancer.
Mohamed M OmranManar S FoudaSara A MekkawyAshraf A TabllAhmed G AbdelazizAzza M OmranTarek M EmranPublished in: Technology in cancer research & treatment (2024)
Colorectal cancer (CRC) is the third most frequently found cancer in the world, and it is frequently discovered when it is already far along in its development. About 20% of cases of CRC are metastatic and incurable. There is more and more evidence that colorectal cancer stem cells (CCSCs), which are in charge of tumor growth, recurrence, and resistance to treatment, are what make CRC so different. Because we know more about stem cell biology, we quickly learned about the molecular processes and possible cross-talk between signaling pathways that affect the balance of cells in the gut and cancer. Wnt, Notch, TGF-β, and Hedgehog are examples of signaling pathway members whose genes may change to produce CCSCs. These genes control self-renewal and pluripotency in SCs and then decide the function and phenotype of CCSCs. However, in terms of their ability to create tumors and susceptibility to chemotherapeutic drugs, CSCs differ from normal stem cells and the bulk of tumor cells. This may be the reason for the higher rate of cancer recurrence in patients who underwent both surgery and chemotherapy treatment. Scientists have found that a group of uncontrolled miRNAs related to CCSCs affect stemness properties. These miRNAs control CCSC functions like changing the expression of cell cycle genes, metastasis, and drug resistance mechanisms. CCSC-related miRNAs mostly control signal pathways that are known to be important for CCSC biology. The biomarkers (CD markers and miRNA) for CCSCs and their diagnostic roles are the main topics of this review study.
Keyphrases
- stem cells
- cancer stem cells
- signaling pathway
- papillary thyroid
- cell cycle
- induced apoptosis
- cell proliferation
- genome wide
- pi k akt
- epithelial mesenchymal transition
- squamous cell carcinoma
- end stage renal disease
- small cell lung cancer
- poor prognosis
- minimally invasive
- lymph node metastasis
- transforming growth factor
- radiation therapy
- mesenchymal stem cells
- genome wide identification
- gene expression
- cell death
- bioinformatics analysis
- prognostic factors
- acute coronary syndrome
- cell therapy
- transcription factor
- percutaneous coronary intervention
- coronary artery bypass
- smoking cessation
- bone marrow
- genome wide analysis
- replacement therapy
- patient reported outcomes